bmy-14802
chemical compound
≈ 2 min read
Names in other languages
- Englishbmy-14802
- shBMY-14802
- СрпскиBMY-14802
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
BMY-14802, also known as BMS-181100, is a drug with antipsychotic effects which acts as both a sigma receptor antagonist and a 5-HT 1A receptor agonist. It also has affinity for the 5-HT 2 and D 4 receptors. The drug reached phase III clinical trials for the treatment of psychosis but was never marketed.
Synthesis
Patent (Ex1/2/5/6/7): The reaction of 4-chloro-4'-fluorobutyrophenone [3874-54-2] (1) with ethylene glycol gives the ketal, 2-(3-chloropropyl)-2-(4-fluorophenyl)-1,3-dioxolane [3308-94-9] (2). The reaction of 2-chloro-5-fluoro-4-methylthiopyrimidine [87789-51-3] (3) with N-carboethoxypiperazine [120-43-4] (4) gives ethyl-4-(5-fluoro-4-methylthio-2-pyrimidinyl)-1-piperazine carboxylate, PC10470079 (5).
Catalytic hydrogenation removes the thiomethyl group giving ethyl-4-(5-fluoro-2-pyrimidinyl)-1-piperazine carboxylate [87789-52-4] (6). Acid hydrolysis of the carbamate protecting group gives a secondary amine and hence 5-fluoro-2-(piperazin-1-yl)pyrimidine [87789-49-9] (7).
Alkylation of 2 with 7 and subsequent hydrolysis of the ketal protecting group afforded 1-(4-fluorophenyl)-4-(4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl)butan-1-one [133982-66-8] (8). Lastly, reduction of the benzoyl ketone with sodium borohydride gave the alcohol, completing the synthesis of BMY-14802 (9).
Text derived from https://en.wikipedia.org/w/index.php?oldid=1370549988 under CC BY-SA 4.0; modifications have been made.